Wuhan Kotei InformaticsLtd Valuation
Is 301221 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 301221 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 301221 (CN¥38.98) is trading above our estimate of fair value (CN¥1.4)
Significantly Below Fair Value: 301221 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 301221?
Other financial metrics that can be useful for relative valuation.
| What is 301221's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥3.61b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | 21.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 301221's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.5x | ||
300996 Pansoft | 4.2x | 21.3% | CN¥3.2b |
301162 State Power Rixin Technology | 9.3x | 24.4% | CN¥4.4b |
300377 Shenzhen Ysstech Info-TechLtd | 2.8x | n/a | CN¥4.5b |
300081 Hengxin Shambala CultureLtd | 9.6x | n/a | CN¥3.8b |
301221 Wuhan Kotei InformaticsLtd | 5.6x | 22.3% | CN¥3.6b |
Price-To-Sales vs Peers: 301221 is good value based on its Price-To-Sales Ratio (5.6x) compared to the peer average (6.5x).
Price to Earnings Ratio vs Industry
How does 301221's PE Ratio compare vs other companies in the CN Software Industry?
Price-To-Sales vs Industry: 301221 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the CN Software industry average (5.1x).
Price to Sales Ratio vs Fair Ratio
What is 301221's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.6x |
| Fair PS Ratio | 2.7x |
Price-To-Sales vs Fair Ratio: 301221 is expensive based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.